John Libbey Eurotext

European Journal of Dermatology

A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience Volume 27, issue 5, September-October 2017

Figures

  • Figure 1
  • Figure 2

Tables

Authors
1 Unit of Dermatology,
University of Padua,
Via Gallucci 4,
35128 Padova,
Italy
2 Unit of Biostatistics,
Epidemiology and Public Health, Department of Cardiac,
Thoracic and Vascular Sciences University of Padua Via Loredan,
18, 35131 Padova,
Italy
3 Unit of Medical Oncology,
Veneto Institute of Oncology IOV-IRCCS,
35128 Padova,
Italy
* Reprints
  • Key words: BRAF inhibitor, cutaneous side effect, MEK inhibitor, melanoma
  • DOI : 10.1684/ejd.2017.3069
  • Page(s) : 482-6
  • Published in: 2017

Melanoma is one of the most fatal cancers and is responsible for 75% of deaths from all skin cancers [1]. In the last decades, its incidence has been increasing worldwide [1]. Patients with advanced melanoma have a poor prognosis with a median survival time of 6-10 months [2]. Prior to the development of new targeted therapies, the only effective treatment for metastatic melanoma was surgery. Radiotherapy and chemotherapy (dacarbazine and other chemotherapeutic agents) did not improve the overall [...]